Skip to main content
. 2021 Jul 28;25(17):8300–8311. doi: 10.1111/jcmm.16782

FIGURE 2.

FIGURE 2

Effects of dasatinib, erlotinib, AG490, LY294002 or PD98059 on expression and phosphorylation of Src, EGFR, STAT‐3, STAT‐5, PKB and ERK‐1/2 in YD‐38 cells and cell survival. A, YD‐38 cells were treated with dasatinib (10 μM) for the indicated times. At each time point, whole‐cell lysates were prepared and analysed by Western blotting. Each picture is representative of three independent experiments. B‐E, YD‐38 cells were treated for 24 h with the indicated doses of erlotinib (B), AG490 (C), LY294002 (D) and PD98059 (E), followed by measurement of cell survival by cell count analysis. Data are mean ±SE of three independent experiments. *P < .05 compared with the values of control (no drug)